These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2838292)

  • 1. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats.
    Gerritsen van der Hoop R; de Koning P; Boven E; Neijt JP; Jennekens FG; Gispen WH
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):637-42. PubMed ID: 2838292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Org.2766 protects from cisplatin-induced neurotoxicity in rats.
    de Koning P; Neijt JP; Jennekens FG; Gispen WH
    Exp Neurol; 1987 Sep; 97(3):746-50. PubMed ID: 3040462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.
    Hamers FP; Pette C; Bravenboer B; Vecht CJ; Neijt JP; Gispen WH
    Cancer Chemother Pharmacol; 1993; 32(2):162-6. PubMed ID: 8387400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence.
    Gerritsen van der Hoop R; Hamers FP; Neijt JP; Veldman H; Gispen WH; Jennekens FG
    J Neurol Sci; 1994 Nov; 126(2):109-15. PubMed ID: 7853014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons.
    Müller LJ; Gerritsen van der Hoop R; Moorer-van Delft CM; Gispen WH; Roubos EW
    Cancer Res; 1990 Apr; 50(8):2437-42. PubMed ID: 2156619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats.
    Van der Zee CE; Van der Hoop RG; Gispen WH
    Diabetes; 1989 Feb; 38(2):225-30. PubMed ID: 2536628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats.
    Hamers FP; van der Hoop RG; Steerenburg PA; Neijt JP; Gispen WH
    Toxicol Appl Pharmacol; 1991 Dec; 111(3):514-22. PubMed ID: 1660632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats.
    Sporel-Ozakat RE; Edwards PM; Van der Hoop RG; Gispen WH
    Eur J Pharmacol; 1990 Sep; 186(2-3):181-7. PubMed ID: 1963145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
    Bravenboer B; Erkelens DW; Gispen WH
    Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
    [No Abstract]   [Full Text] [Related]  

  • 10. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats.
    Hamers FP; Pette C; Neijt JP; Gispen WH
    Eur J Pharmacol; 1993 Mar; 233(1):177-8. PubMed ID: 8097161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACTH4-9 analogue ORG 2766 can improve existing neuropathy in streptozocin-induced diabetic rats.
    Bravenboer B; Kappelle AC; van Buren T; Erkelens DW; Gispen WH
    Acta Diabetol; 1993; 30(1):21-4. PubMed ID: 8392402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial.
    van Gerven JM; Hovestadt A; Moll JW; Rodenburg CJ; Splinter TA; van Oosterom AT; Keizer L; Drogendijk TE; Groenhout CM; Vecht CJ
    J Neurol; 1994 Jun; 241(7):432-5. PubMed ID: 7931444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat.
    De Koning P; Gispen WH
    Peptides; 1987; 8(3):415-22. PubMed ID: 2821519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACTH/MSH like peptides in the treatment of cisplatin neuropathy.
    Gispen WH; Hamers FP; Vecht CJ; Jennekens FG; Neyt JP
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):179-83. PubMed ID: 1326318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study.
    Hilkens PH; van der Burg ME; Moll JW; van den Bent MJ; van Putten WL; Vecht CJ
    Clin Neurol Neurosurg; 1995 May; 97(2):139-41. PubMed ID: 7656487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of cisplatin-induced neuropathy: recent developments.
    Hamers F; Neijt J; Gispen W
    Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection by an ACTH4-9 analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro.
    Hol EM; Mandys V; Sodaar P; Gispen WH; Bär PR
    J Neurosci Res; 1994 Oct; 39(2):178-85. PubMed ID: 7837287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
    Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
    J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for preventing neuropathy caused by cisplatin and related compounds.
    Albers J; Chaudhry V; Cavaletti G; Donehower R
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
    Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
    Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.